Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341196 | 0.94 | HTR6 (0.48) | HTR6PKMPOLBGAANR3C2 | |
| SCHEMBL3343504 | 0.87 | HTR6 (0.48) | HTR6PKMPOLBGAANR3C2 | |
| SCHEMBL3571632 | 0.87 | HTR6 (0.63) | HTR6PKMPOLBGAANR3C2 | |
| SCHEMBL3341141 | 0.86 | HTR6 (0.54) | HTR6PKMHTR1ADRD2HTR2A | |
| SCHEMBL3338525 | 0.84 | HTR6 (0.53) | HTR6PKMHTR1AKMT2ADRD2 | |
| SCHEMBL3617684 | 0.84 | HTR6 (0.47) | HTR6HTR1AHTR1DHTR1BSLC6A4 | |
| SCHEMBL3625114 | 0.83 | NR3C2 (0.44) | HTR6PKMPOLBGAANR3C2 | |
| SCHEMBL3339339 | 0.83 | HTR6 (0.51) | HTR6PKMHTR1ADRD2HTR2A | |
| SCHEMBL3340161 | 0.82 | HTR6 (0.57) | HTR6PKMPOLBGAANR3C2 | |
| SCHEMBL3337575 | 0.82 | HTR6 (0.51) | HTR6PKMHTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130295325-A1 | METHOD OF FORMING A POLYMER SUBSTRATE WITH VARIABLE REFRACTIVE INDEX SENSITIVITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-11-07 | — | — | US | claimed |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-06-17 | — | — | US | claimed |
| EP-2118184-A1 | HIGH SELECTIVITY POLYMER-NANO-POROUS PARTICLE MEMBRANE STRUCTURES | Board of Regents, The University of Texas System (US) | 2009-11-18 | — | — | EP | claimed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| EP-1984351-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| WO-2008112745-A1 | HIGH SELECTIVITY POLYMER-NANO-POROUS PARTICLE MEMBRANE STRUCTURES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | claimed |
| WO-2007098418-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-08-30 | — | — | WO | claimed |
| US-6114495-A | POLYLACTIDE POLYMER HAVING A NUMBER AVERAGE MOLECULAR WEIGHT OF BETWEEN ABOUT 25,000 AND ABOUT 200,000, LACTIDE, IF PRESENT AT ALL, PRESENT IN CONCENTRATION OF LESS THAN 0.5 WT % BASED ON WEIGHT OF COMPOSITION, DEACTIVATING AGENTS | CARGILL INCORPORATED (US) | 2000-09-05 | — | — | US | claimed |
| US-20180151885-A1 | DISCRETE CARBON NANOTUBES AND MICROFIBER COMPOSITES | MOLECULAR REBAR DESIGN LLC (US) | 2018-05-31 | — | — | US | disclosed |
| EP-1070097-B1 | LACTIC ACID RESIDUE CONTAINING POLYMER COMPOSITION, PRODUCT, METHOD FOR PREPARATION AND USE | CARGILL INC (US) | 2016-02-17 | — | — | EP | disclosed |
| US-9011705-B2 | Method of forming a polymer substrate with variable refractive index sensitivity | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-04-21 | — | — | US | disclosed |
| US-20130295325-A1 | METHOD OF FORMING A POLYMER SUBSTRATE WITH VARIABLE REFRACTIVE INDEX SENSITIVITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-11-07 | — | — | US | disclosed |
| US-8211951-B2 | High selectivity polymer-nano-porous particle membrane structures | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-07-03 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | MEMORY PHARMACEUTICALS CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-6353086-B1 | COMPOSITION COMPRISING POLYLACTIDE POLYMER HAVING SPECIFIED NUMBER AVERAGE MOLECULAR WEIGHT, LOW CONCENTRATION OF LACTIDE, CATALYST DEACTIVATING AGENT HAVING SPECIFIED MOLECULAR WEIGHT AND MORE THAN TWO CARBOXYLIC ACID GROUPS PER MOLECULE | CARGILL, INCORPORATED | 2002-03-05 | — | — | US | disclosed |
| EP-1070097-A1 | LACTIC ACID RESIDUE CONTAINING POLYMER COMPOSITION, PRODUCT, METHOD FOR PREPARATION AND USE | Cargill, Incorporated (US) | 2001-01-24 | — | — | EP | disclosed |
| US-6114495-A | POLYLACTIDE POLYMER HAVING A NUMBER AVERAGE MOLECULAR WEIGHT OF BETWEEN ABOUT 25,000 AND ABOUT 200,000, LACTIDE, IF PRESENT AT ALL, PRESENT IN CONCENTRATION OF LESS THAN 0.5 WT % BASED ON WEIGHT OF COMPOSITION, DEACTIVATING AGENTS | CARGILL INCORPORATED (US) | 2000-09-05 | — | — | US | disclosed |
| WO-1999050345-A1 | LACTIC ACID RESIDUE CONTAINING POLYMER COMPOSITION, PRODUCT METHOD FOR PREPARATION AND USE | CARGILL, INCORPORATED (US) | 1999-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | HTR6 1/4885PKM 1936/4885POLB 4064/4885 |
| US-20100152177-A1 | COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3B, HTR1B | HTR6 1/4885PKM 3353/4885POLB 3241/4885 |
| US-20080039462-A1 | Compounds having 5-HT6 receptor affinity | HTR6, HTR3B, HTR1B | HTR6 1/4885PKM 3353/4885POLB 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.